[1] Lambert S J, Thomas K V, Davy A J. Assessment of the risk posed by the antifouling booster biocides Irgarol 1051 and diuron to freshwater macrophytes [J]. Chemosphere, 2006, 63(5):734-43.
[2] Thomas K V. Environmental fate and behaviour of antifouling paint booster biocides: a review[J]. Biofouling, 2001, 17(1): 73-86.
[3] Zhou J L. Occurrence and persistence of antifouling biocide Irgarol 1051 and its main metabolite in the coastal waters of Southern England[J]. Science of the Total Environment, 2008, 406(1/2):239-246.
[4] Lam K H, Lam M H W, Lam P K S, et al. Identification and characterization of a new degradation product of Irgarol-1051 in mercuric chloride-catalyzed hydrolysis reaction and in coastal waters[J]. Marine Pollution Bulletin, 2004, 49(4): 361-367.
[5] Okamura H, Aoyama I, Takami T, et al. Phytotoxicity of the new antifouling compound Irgarol 1051 and major degradation product[J]. Marine Pollution Bulletin, 2000, 40(9): 754-763.
[6] Lam K H, Wai H Y, Leung K M Y, et al. A study of the partitioning behavior of Irgarol-1051 and its transformation products[J]. Chemosphere, 2006, 64(7): 1177-1184.
[7] Hu W, Jones P D, Celius T, et al. Identification of genes responsive to PFOS using gene expression profiling[J]. Environmental Toxicology and Pharmacology, 2005, 19(1):57-70.
[8] Ciba-Geigy. Irgarol 1051 in Antifouling paints[R]. Basle, Switzerland: Giba-Geigy Ltd, 1995.
[9] Yeung L W, Gurugea K S, Yamanaka N, et al. Differential expression of chicken hepatic genes responsive to PFOA and PFOS[J]. Toxicology, 2007, 237(1/2/3):111-125.
[10] Heinloth A N, Irwin R D, Boorman G A, et al. Gene expression profiling of rat livers reveals indicators of potential adverse effects[J]. Toxicological Sciences, 2004, 80(1): 193-202.
[11] Guruge K S, Yeung L W, Yamanaka N, et al. Gene expression profiles in rat liver treated with perfluorooctanoic acid(PFOA)[J]. Toxicological Sciences, 2006, 89(1): 93-107.
[12] Lynn F C, Pamir N, Ng E H, et al. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty zucker rats[J]. Diabetes, 2001, 50(5): 1004-1011.
[13] Heilker R, Wolff M, Tautermann C S, et al. G-protein-coupled receptor-focused drug discovery using a target class platform approach[J]. Drug Discovery Today, 2009, 14(5/6):231-240.
[14] Alvarez R D, Canessa C M, Fyfe G K, et al. Structure and regulation of amiloride-sensitive sodium channels[J]. Annual Review of Physiology. 2000, 62:573-94.
[15] Butterworth M B. Regulation of the epithelial sodium channel(ENaC)by membrane trafficking[J]. Biochimica et Biophysica Acta(BBA)-Molecular Basis of Disease, 2010, 1802(12):1166-1177.